ADVANCING ORPHAN ONCOLOGY
About us
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway.
Headquarter is in Malmö, Sweden, and the company’s shares are listed on Nasdaq Stockholm (ticker: ACE)
Download our fact sheet: Ascelia Pharma Factsheet Dec 2020
Latest presentations
Company presentation (pdf)
Latest news
- 2021-02-16Quarterly Report Q4 2020: Mangoral shows high diagnostic value in new study
- 2021-01-14Information regarding transfer of shares in Ascelia Pharma AB from CMC SPV
- 2021-01-12Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy
- 2020-12-15Ascelia Pharma gets US patent for second generation Mangoral
- 2020-12-02New study shows Mangoral’s lesion visualization as effective as gadolinium contrast agent
Events
- March 10 @ 16:50 - 17:20
Life Science Investor conference
- March 16 @ 17:30 - 18:00
Aktiedagen Stockholm 16–17 March 2021 (digital event)
- March 23 - March 24
Stockholm Corporate Finance Life Science seminarium
- May 5 @ 14:00 - 16:00
Annual General Meeting 2021
- May 12 @ 08:00
Interim Report Q1 2021 (January-March 2021)